Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | DHFR | P00374 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30187451 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL13518567 | 0.99 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| SCHEMBL1702113 | 0.85 | IGF1R (0.61) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| SCHEMBL1702887 | 0.81 | PDGFRB (0.62) | SMN1; SMN2NPC1RAB9AMEN1MAPT | |
| SCHEMBL1705284 | 0.81 | DHFR (0.54) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| SCHEMBL1702586 | 0.80 | RAB9A (0.61) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| SCHEMBL31098987 | 0.80 | RAB9A (0.61) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| SCHEMBL1702296 | 0.80 | SCN9A (0.52) | SMN1; SMN2NPC1RAB9AMEN1MAPT | |
| SCHEMBL30764813 | 0.79 | NPC1 (0.55) | SMN1; SMN2HTTNPC1RAB9AMEN1 | |
| SCHEMBL21617086 | 0.79 | NPC1 (0.55) | SMN1; SMN2HTTNPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517534-B1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2024-02-28 | — | — | EP | claimed |
| EP-3645029-B1 | TREATMENTS TO ELIMINATE HIV RESERVOIRS AND REDUCE VIRAL LOAD | PASTEUR INSTITUT (FR) | 2023-01-18 | — | — | EP | claimed |
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | claimed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| EP-2261214-A1 | Compounds useful to treat premature aging and in particular progeria | Splicos Sas (FR) | 2010-12-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | SMN1; SMN2 4057/4885HTT 3087/4885NPC1 7/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | SMN1; SMN2 4559/4885HTT 4624/4885NPC1 45/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | SMN1; SMN2 4495/4885HTT 4167/4885NPC1 129/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | SMN1; SMN2 1391/4885HTT 929/4885NPC1 144/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | SMN1; SMN2 4057/4885HTT 3087/4885NPC1 7/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | SMN1; SMN2 2094/4885HTT 2082/4885NPC1 126/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | SMN1; SMN2 4475/4885HTT 4207/4885NPC1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.